2. Academic Validation
  3. Molybdenum Nanodots for Acute Lung Injury Therapy

Molybdenum Nanodots for Acute Lung Injury Therapy

  • ACS Nano. 2023 Dec 12;17(23):23872-23888. doi: 10.1021/acsnano.3c08147.
Jiayang Yan 1 2 3,  Zhongmin Tang 4,  Yanan Li 1 2 3,  Han Wang 5,  Jessica C Hsu 4,  Mengmeng Shi 1 2 3,  Zi Fu 5,  Xiuru Ji 5,  Weibo Cai 4,  Dalong Ni 5,  Jieming Qu 1 2 3
Affiliations

Affiliations

  • 1 Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • 2 Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • 3 Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai 200025, China.
  • 4 Departments of Radiology and Medical Physics, University of Wisconsin, Madison, Wisconsin 53705, United States.
  • 5 Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
PMID: 38084420 DOI: 10.1021/acsnano.3c08147
Abstract

Acute respiratory disease syndrome (ARDS) is a common critical disease with high morbidity and mortality rates, yet specific and effective treatments for it are currently lacking. ARDS was especially apparent and rampant during the COVID-19 pandemic. Excess Reactive Oxygen Species (ROS) production and an uncontrolled inflammatory response play a critical role in the disease progression of ARDS. Herein, we developed molybdenum nanodots (MNDs) as a functional nanomaterial with ultrasmall size, good biocompatibility, and excellent ROS scavenging ability for the treatment of acute lung injury (ALI). MNDs, which were administered intratracheally, significantly ameliorated lung oxidative stress, inflammatory response, protein permeability, and histological severity in ALI mice without inducing any safety issues. Importantly, transcriptomics analysis indicated that MNDs protected lung tissues by inhibiting the activation of the NOD-like Receptor protein 3 (NLRP3)-dependent pyroptotic pathway. This work presents a promising therapeutic agent for patients suffering from ARDS.

Keywords

acute lung injury; acute respiratory disease syndrome; antioxidants; molybdenum; nanomedicine; reactive oxygen species.

Figures
Products